Researchers reported that PD-1 and LAG-3 double-positive T cells inside gastric tumors are associated with improved survival, according to a study published in Medical Oncology. The finding points to a potentially actionable immune subset that may help explain why patients with similar diagnoses can experience different clinical courses. While the report is not a drug trial, it adds evidence that spatial and phenotypic immune profiling can refine prognosis in solid tumors. For biotech teams, the translational relevance is immediate: these types of markers can become inclusion criteria, stratification tools, or endpoints in next-generation immunotherapy trials. The update reinforces how immune exhaustion and immune competence markers are increasingly used to translate tumor microenvironment biology into patient-level risk stratification.